首页 | 本学科首页   官方微博 | 高级检索  
     

重组人p53腺病毒注射液联合顺铂与紫杉醇治疗晚期宫颈癌的疗效及安全性分析
引用本文:薛艳军,林丽红,高雁荣,马媛,韩金利,程勇. 重组人p53腺病毒注射液联合顺铂与紫杉醇治疗晚期宫颈癌的疗效及安全性分析[J]. 临床医学工程, 2021, 0(4): 437-438
作者姓名:薛艳军  林丽红  高雁荣  马媛  韩金利  程勇
作者单位:安阳市肿瘤医院妇科;安阳市肿瘤医院检验科;安徽省立医院妇科
基金项目:安徽省自然科学基金项目(项目编号:1308085MH122)。
摘    要:目的 探讨重组人p53腺病毒注射液联合顺铂与紫杉醇治疗晚期宫颈癌的疗效及安全性.方法 80例晚期宫颈癌患者随机分为两组各40例,对照组给予顺铂与紫杉醇治疗,研究组在对照组基础上给予重组人p53腺病毒注射液治疗.比较两组的治疗效果、不良反应以及复发率、转移率、死亡率.结果 研究组的治疗总有效率高于对照组,1年内病死率、复...

关 键 词:晚期宫颈癌  重组人p53腺病毒注射液  顺铂  紫杉醇  疗效

Analysis on the Efficacy and Safety of Recombinant Human p53 Adenovirus Injection Combined with Cisplatin and Paclitaxelin the Treatment of Advanced Cervical Cancer
XUE Yanjun,LIN Lihong,GAO Yanrong,MA Yuan,HAN Jinli,CHENG Yong. Analysis on the Efficacy and Safety of Recombinant Human p53 Adenovirus Injection Combined with Cisplatin and Paclitaxelin the Treatment of Advanced Cervical Cancer[J]. Medical and Health Care Instruments, 2021, 0(4): 437-438
Authors:XUE Yanjun  LIN Lihong  GAO Yanrong  MA Yuan  HAN Jinli  CHENG Yong
Affiliation:(Department of Gynecology,Anyang Cancer Hospital,Anyang 455000,China;Clinical Laboratory,Anyang Cancer Hospital,Anyang 455000,China;Department of Gynecology,Anhui Provincial Hospital,Hefei 230001,China)
Abstract:Objective To explore the efficacy and safety of recombinant human p53 adenovirus injection combined with cisplatin and paclitaxel in the treatment of advanced cervical cancer.Methods 80 patients with advanced cervical cancer were randomly divided into two groups,with 40 cases in each group.The control group was treated with cisplatin and paclitaxel,and the study group was treated with recombinant human p53 adenovirus injection on the basis of the control group.The therapeutic effect,adverse reactions,recurrence rate,metastasis rate and mortality rate were compared between two groups.Results The total effective rate of study group was higher than that of control group,and the mortality rate,recurrence rate and metastasis rate within 1 year were lower than those of control group(P<0.05).No significant difference was found in the incidence of adverse reactions between two groups(P>0.05).Conclusions Recombinant human p53 adenovirus injection combined with cisplatin and paclitaxel in the treatment of advanced cervical cancer has significant efficacy and high safety,and can effectively reduce the recent death,recurrence and metastasis.
Keywords:Advanced cervical cancer  Recombinant human p53 adenovirus injection  Cisplatin  Paclitaxel  Efficacy
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号